000			03232nam a22003737a 4500
008			220706s20222022 xxu||||| |||| 00| 0 eng d
022			_a2168-8184
024			_a10.7759/cureus.24576 [doi]
024			_aPMC9138632 [pmc]
040			_aOvid MEDLINE(R)
099			_a35651376
245			_aLower Rates of Hepatocellular Carcinoma Observed Among Cannabis Users: A Population-Based Study.
251			_aCureus. 14(4):e24576, 2022 Apr.
252			_aCureus. 14(4):e24576, 2022 Apr.
253			_aCureus
260			_c2022
260			_fFY2022
260			_p2022 Apr
265			_sepublish
265			_tPubMed-not-MEDLINE
266			_d2022-07-06
520			_aBACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and the fourth leading cause of cancer deaths in the world. The association between HCC and cannabis has been identified in mice; however, to our knowledge has not been identified in humans. Therefore, we aim to investigate the relation between HCC and cannabis use in humans.
520			_aCONCLUSION: Based on our large database analysis, we found that cannabis use patients were 55% less likely to have HCC compared to patients without cannabis use. Further prospective studies are needed to assess the role of cannabis use on HCC. Copyright © 2022, ElTelbany et al.
520			_aMETHODS: Using data from the National Inpatient Sample (NIS) database between 2002 and 2014, we identified the patients with HCC and cannabis use diagnosis using the International Classification of Disease 9th version codes (ICD-9). Then, we identified patients without cannabis use as the control group. We adjusted for multiple potential confounders and performed multivariable logistic regression analysis to determine the association between cannabis abuse and HCC.
520			_aRESULTS: A total of 101,231,036 patients were included in the study. Out of the total, 996,290 patients (1%) had the diagnosis of cannabis abuse versus 100,234,746 patients (99%) in the control group without cannabis abuse. We noticed that patients with cannabis abuse were younger (34 vs 48 years), had more males (61.7% vs 41.4%) and more African Americans (29.9% vs 14.2%) compared with the control group (P<0.001 for all). Besides, patients with cannabis use had more hepatitis B, hepatitis C, liver cirrhosis, and smoking, but had less obesity and gallstones, (P<0.001 for all). Using multivariable logistic regression, and after adjusting for potential confounders, patients with cannabis abuse were 55% less likely to have HCC (adjusted Odds Ratio {aOR}, 0.45, 95% Confidence Interval {CI}, 0.42-0.49, P<0.001) compared with patients without cannabis abuse.
546			_aEnglish
656			_aGastroenterology Fellowship
656			_aMedStar Georgetown University Hospital/MedStar Washington Hospital Center
657			_aJournal Article
700			_aKhoudari, George _bMedStar Georgetown University Hospital/MedStar Washington Hospital Center _cGastroenterology Fellowship
790			_aAl-Khadra Y, Alkhouri N, ElTelbany A, Khoudari G, McCullough A
856			_uhttps://dx.doi.org/10.7759/cureus.24576 _zhttps://dx.doi.org/10.7759/cureus.24576
942			_cART _dArticle
999			_c421 _d421